Pfizer Inc. (FRA:PFE)
| Market Cap | 128.61B -10.6% |
| Revenue (ttm) | 53.30B -1.6% |
| Net Income | 6.62B -3.2% |
| EPS | 1.16 -3.4% |
| Shares Out | n/a |
| PE Ratio | 19.43 |
| Forward PE | 8.96 |
| Dividend | 1.49 (6.57%) |
| Ex-Dividend Date | Jan 23, 2026 |
| Volume | 8,109 |
| Average Volume | 10,629 |
| Open | 22.93 |
| Previous Close | 22.71 |
| Day's Range | 22.40 - 22.93 |
| 52-Week Range | 18.77 - 25.71 |
| Beta | n/a |
| RSI | 49.97 |
| Earnings Date | Feb 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
BioNTech sues Moderna for patent infringement over COVID-19 shots
German biopharmaceutical company BioNTech 22UAy.DE sued Moderna MRNA.O in Delaware federal court on Thursday, alleging that Moderna’s COVID-19 vaccine mNEXSPIKE infringes a patent related to BioNTech ...
Global Respiratory Syncytial Virus (RSV) Vaccines Market to Reach $1.24 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The global Respiratory Syncytial Virus (RSV) vaccines market is entering a critical phase of maturation and strategic realignment, with valuation pr...
Top High-Yield Stocks to Double Up on Right Now
Pfizer has made the investments needed to get its drug pipeline back on track. United Parcel Service's turnaround effort is starting to show progress.
Vanguard Russell 1000 Index Fund Buys 21,811 Shares of Pfizer Inc (PFE)
Vanguard Russell 1000 Index Fund Buys 21,811 Shares of Pfizer Inc (PFE)
Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare Stomach Cancer
Zinger Key Point: MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical-stage bi...
Notable ETF Outflow Detected - XLV, ABT, PFE, DHR
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where we...
Pfizer (PFE) Experiences Mixed Options Sentiment Amid Downgrade
Pfizer (PFE) Experiences Mixed Options Sentiment Amid Downgrade
Is There 25% Downside For Pfizer Stock?
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price ...
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
Vanguard U.S. Multifactor ETF Buys 136,230 Shares of Pfizer Inc (PFE)
Vanguard U.S. Multifactor ETF Buys 136,230 Shares of Pfizer Inc (PFE)
Vanguard Russell 1000 Value Index Fund Buys 22,536 Shares of Pfizer Inc (PFE)
Vanguard Russell 1000 Value Index Fund Buys 22,536 Shares of Pfizer Inc (PFE)
Vanguard U.S. Value Factor ETF Sells 11,484 Shares of Pfizer Inc (PFE)
Vanguard U.S. Value Factor ETF Sells 11,484 Shares of Pfizer Inc (PFE)
Vanguard Global Wellington Fund Sells 12,152 Shares of Pfizer Inc (PFE)
Vanguard Global Wellington Fund Sells 12,152 Shares of Pfizer Inc (PFE)
Pfizer: The Rebound Looks Unsustainable
How Is The Market Feeling About Pfizer Inc?
Pfizer Inc's (NYSE: PFE) short interest as a percent of float has risen 10.53% since its last report. According to exchange reported data, there are now 143.04 million shares sold short , which is 2....
Pfizer's (PFE) Braftovi Shows Promise in Colorectal Cancer Trial
Pfizer's (PFE) Braftovi Shows Promise in Colorectal Cancer Trial
Pfizer says cancer therapy Braftovi improved survival in late-stage trial
BLUEPRINT ADAPTIVE GROWTH ALLOCATION FUND Buys 536 Shares of Pfizer Inc (PFE)
BLUEPRINT ADAPTIVE GROWTH ALLOCATION FUND Buys 536 Shares of Pfizer Inc (PFE)
Xtrackers US National Critical Technologies ETF Buys 324 Shares of Pfizer Inc (PFE)
Xtrackers US National Critical Technologies ETF Buys 324 Shares of Pfizer Inc (PFE)
PGIM Quant Solutions Large-Cap Value Fund Buys 5,400 Shares of Pfizer Inc (PFE)
PGIM Quant Solutions Large-Cap Value Fund Buys 5,400 Shares of Pfizer Inc (PFE)
Pfizer (PFE) Reports Positive Results from BREAKWATER Trial in mCRC
Pfizer (PFE) Reports Positive Results from BREAKWATER Trial in mCRC
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI (encor...
Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial,...
Avantis U.S. Equity ETF Buys 52,222 Shares of Pfizer Inc (PFE)
Avantis U.S. Equity ETF Buys 52,222 Shares of Pfizer Inc (PFE)